Vestal Point Capital’s Soleno Therapeutics SLNO Stock Holding History

Vestal Point Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-730,000	Closed	-$24.4M	–	89
2026 Q1	$24.4M	Buy	+730,000	New	+$28.6M	0.68%	46
2025 Q1	–	Sell	-1,060,000	Closed	-$47.6M	–	80
2024 Q4	$47.6M	Buy	1,060,000 +340,000	+47%	+$17.6M	2.82%	9
2024 Q3	$36.4M	Sell	720,000 -480,000	-40%	-$23M	2.76%	12
2024 Q2	$49M	Sell	1,200,000 -50,000	-4%	-$2.12M	3.65%	8
2024 Q1	$53.5M	Sell	1,250,000 -50,000	-4%	-$2.26M	4.42%	6
2023 Q4	$52.3M	Buy	+1,300,000	New	+$37M	5.54%	5

Vestal Point Capital's SLNO Position: Q2 2026 in Review

Vestal Point Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 730,000 shares — an estimated $24.4M sold.

Vestal Point Capital first reported a position in SLNO in Q4 2023 and held it in 6 quarters. The position peaked at $53.5M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Vestal Point Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 730,000 Soleno Therapeutics shares in Q2 2026, an estimated $24.4M.
Vestal Point Capital first reported a position in Soleno Therapeutics in Q4 2023 and held it in 6 quarters.
Vestal Point Capital's Soleno Therapeutics position peaked at $53.5M in Q1 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.